ABSTRACT COMPANION (Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure), the first cardiac resynchronization therapy (CRT)-heart failure mortality and morbidity controlled clinical trial planned, conducted, and reported, was a randomized, 3-arm study that compared CRT delivered by a biventricular pacemaker (CRT-P) or a CRT defibrillator device (CRT-D) with optimal pharmacological therapy alone. The patient population had advanced chronic heart failure with QRS interval prolongation $120 ms and reduced left ventricular ejection fraction (heart failure with reduced ejection fraction). COMPANION had a composite hospitalization and mortality endpoint as the primary outcome measure but was also powered for mortality as the first secondary endpoint. The conduct of COMPANION was challenged by important issues that arose during the trial, the most important of which was U.S. Food and Drug Administration approval of CRT devices. Along with other challenges, this issue was appropriately dealt with by the Steering Committee and the Data and Safety Monitoring Committee and did not negatively affect trial results or conclusions. We report here updated analyses from the study, which are consistent with previously published results indicating that CRT-P or CRT-D has favorable effects on heart failure morbidity and mortality in a patient population "precision" selected by the surrogate marker of increased QRS interval duration. New analyses indicate that increasing the number of classes of neurohormonal inhibitor concurrent therapy has a positive effect on CRT mortality reduction. Hypothesis-generating new findings are that in patients receiving beta-blocker therapy, the mortality reduction advantage of CRT-D versus CRT-P may be minimized or eliminated and that there may be adverse effects of CRT-D defibrillator shocks on pump failure-related outcomes. (J Am Coll Cardiol HF 2016;-:---)
(1) and the design-related, subsequently conducted CARE-HF (Cardiac Resynchronization-Heart Failure)
trial (2) have been widely reported, many of the clinical trial issues, investigational insights, and effectiveness outcomes from COMPANION have not been comprehensively described in an integrated fashion.
The purpose of this report is to present and discuss some of the lessons learned and insights gained from occurs in 15% to 30% of patients with chronic
HFrEF (3, 4) . IVCD-associated mechanical dyssynchrony reduces LV systolic function and increases risk for cardiovascular morbidity and mortality (3, 4) . IVCDassociated mechanical dyssynchrony can be corrected with biventricular (5-9) or LV (6, 7) pacing, termed cardiac resynchronization therapy (CRT). When measured by sensitive methods, systolic function was shown to improve in all left ventricles investigated in these pioneering studies (7, 9, 10) . Early studies measuring functional capacity (11, 12) , the energetic cost of improved LV chamber contractility (10) , and reverse remodeling (13) suggested that CRT had the potential to reduce major clinical endpoint outcomes in HFrEF, and implantable cardioverterdefibrillators (ICDs) had been shown to reduce mortality risk in patients with ischemic cardiomyopathy and no sustained ventricular arrhythmias (14, 15) . On the basis of these data, the heart failure investigators involved in the planning of COMPANION recommended to the sponsor that a major heart failure clinical outcomes trial be performed, evaluating the effects of both CRT with only pacing capability The trial was unblinded because of ethical concerns related to implanting a nonfunctioning medical device for a substantial amount of time (median follow-up was anticipated to be at least 1 year) in the OPT arm. The primary outcome was time to the first occurrence of the composite of ACM, ACH, or its equivalent using Kaplan-Meier methodology (18, 19) .
Two scenarios for treatment of decompensated heart failure with intravenous medications were considered to be the equivalent of heart failure hospitalization (HFH) or ACH (1) . ACM was the highest order secondary outcome in the COMPANION protocol 
Lessons and Insights From the COMPANION Trial and right ventricular septum. In both panels, the blue line is the His-Purkinje system and the dashed line is cardiac myocyte depolarization. AV ¼ atrioventricular. Table 1 .
O p e r a t i o n a l c h a l l e n g e s . In addition, the loss of patients from the OPT-alone arm, which by design had only one-fifth of patients randomized, resulted in a loss of power to detect an intervention effect. Increasing the impact of the differential withdrawal rate was that patients who dropped out of the OPT-alone arm did so by withdrawing consent, with most of them in effect crossing over and receiving CRT devices. Once the crossover rate began to escalate, the Steering Committee, sponsor, and FDA agreed to attempt to stem this practice by assigning a class I deviation to the responsible investigator, which carries substantial regulatory implications. This "enforcement" policy was unsuccessful and instead increased incentive to withdraw consent for the study prior to crossover. In such patients, the primary outcome could not be However, such an adjustment cannot compensate for increased dropout and crossovers. Fortunately, the control arm (OPT) event rate and to a lesser extent the CRT arms' effect sizes were able to compensate for the dropout and crossover problems.
Key to addressing the concern over bias related to a differential dropout rate was the robustness of the primary outcome and its components. All-cause death is not subject to bias as long as follow-up is complete. However, hospitalizations may be trig- 
Bristow et al. Table 3 . In line with the inclusion criteria, the COMPANION study population was unambiguously advanced, high-risk HFrEF, all New York Heart Association class III or IV (with 14% class IV), age 67 years, 55% ischemic heart disease, and an average 6-min walk distance of 262 m.
Pharmacologic therapy was likely close to optimal for what can be delivered to such a HFrEF IVCD population, with 89% of subjects on ACE inhibitors or ARBs, 68% on beta-blockers, and 55% on spironolactone. On the basis of clinic visit medication records, 61% of subjects were actually receiving ACE inhibitors or ARBs plus beta-blockers, and 34% were receiving ACE inhibitors or ARBs, beta-blockers, and spironolactone (Online Table 3 ).
P r e d i c t e d v e r s u s a c t u a l r e s u l t s . As presented in Table 1 , there was reasonable agreement between pretrial assumptions and observed results, with the OPTalone group having a primary endpoint event rate higher than expected (observed 67.5% vs. predicted 40%). The secondary (ACM) endpoint was slightly less than expected (18.5% vs. 24% from time-to-event analysis at 12 months) but was 25% when entire trial event rates were normalized to 12-month follow-up.
Effect sizes for the primary endpoint were somewhat less than predicted in both device arms (18% to 19% observed vs. 25% predicted) but were greater than expected for ACM in the CRT-D arm (36% vs. 25% predicted). As a result of the higher than expected control arm (OPT alone) event rate, the absolute reduction in the primary endpoint rate was approximately 11.5% (from 67.5% to w56%) (Online Table 4) in both device arms compared with the predicted absolute event rate reduction of 40% to 30%, or by 10%. In terms of statistical power, for the primary endpoint, slightly lower than expected effect sizes were balanced by a higher than expected control arm event rate, leading to a slightly higher than expected absolute event rate reduction in both device arms.
For the ACM secondary endpoint, a slightly lower than expected OPT arm 12-month event rate was overcome by a higher than expected effect size in the CRT-D arm.
CRT-P (Plus OPT) or CRT-D (Plus OPT) versus OPT
alone. Figure 3A presents Figure 3D ), data similar to those previously published (1) . Hazard ratios for these endpoints as well as for additional clinical endpoints are given in Online Table 3 . As expected, for CRT-P, there is a progressive decrease in the hazard ratio as the combined endpoints become more cardiac and heart failure specific, ranging from 0.82 to 0.66 to 0.64 going from ACM or ACH to ACM or HFH to cardiovascular mortality (CVM) or HFH, respectively. This supports the mechanism of action of CRT as being specific to the failing heart.
The hazard ratios for various endpoints given in
Online Table 4 and the cognate effect sizes in Online Table 5 , on a background of the most effective pharmacological therapy, indicate very large and meaningful treatment effects that are comparable with or exceed the largest effect sizes observed in placebocontrolled pharmacological therapy HFrEF trials, most of which were generated on backgrounds of fewer effective drug classes (27-33) (Online Table 5 ).
FIGURE 3 Time to Study Endpoints (A) Time to all-cause mortality (ACM) or all-cause hospitalization (ACH) (primary endpoint). (B) Time to ACM (secondary endpoint). (C) Time to ACM or cardiovascular hospitalization (CVH). (D)
Time to ACM or heart failure hospitalization (HFH). Reprinted, with permission, from the New England Journal of Medicine. CI ¼ confidence interval; other abbreviations as in Figure 1 .
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Bristow et al. Figure 4 gives time-to-event curves for the primary endpoint or ACM in the 61% of patients who were actually receiving ACE inhibitors or ARBs plus beta-blockers ("double neurohormonal inhibition"), during the trial. Both
NEW ANALYSES. E f f e c t s o f C R T -P o r C R T -D i n p a t i e n t s r e c e i v i n g m u l t i p l e N H I s .
CRT-P and CRT-D were highly effective in the presence of these mainstay HFrEF pharmacological classes, with hazard ratios that were numerically lower (Online Table 4 ) and effect sizes that were higher (Online Table 5 Bristow et al.
Lessons and Insights From the COMPANION Trial Table 2 ).
For SCD, the NNT is 29 for CRT-D versus OPT alone
FIGURE 4 Time to Study Endpoints by Medication
Time to all-cause mortality (ACM) or all-cause hospitalization (ACH) (A), ACM (B), or ACM or heart failure hospitalization (HFH) (C) in patients receiving angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and beta-blockers. Time to ACM or ACH (D), ACM (E), or ACM or HFH (F) in patients receiving ACEIs or ARBs, beta-blockers, and spironolactone (SPL). Abbreviations as in Figures 1 and 3 .
Continued on the next page
Bristow et al. [Online Table 5 ], both hazard ratios significant vs.
OPT [Online Table 4 ]). The same phenomenon is observed for CVM (Online Tables 4 and 5), although neither CRT-D nor CRT-P is statistically significant compared with OPT. The loss of a differential effect on mortality by CRT-D versus CRT-P is not due to the disappearance of a protective effect against SCD in the double neurohormonal inhibition cohort but rather to a higher PFD hazard ratio in CRT-D (Online Table 4 ). In the 34% of patients who were on triple neurohormonal inhibition therapy, both CRT-P and CRT-D reduced mortality as in the double neurohormonal inhibition patients, by the very substantial amounts of 51% and 56%, respectively. An increase in the PFD hazard ratio in the CRT-D arm versus CRT-P is Continued on the next page
Lessons and Insights From the COMPANION Trial -2 0 1 6 : ---not as apparent as in the double neurohormonal inhibition subgroup, but CRT-P significantly reduced PFD (by 63%) (Online Table 4 ) whereas CRT-D did not (nonsignificant 50% decrease).
Could the loss of any benefit on PFD in the CRT-D group in double and possibly triple neurohormonal inhibition patients be due to the adverse effects of defibrillator shocks? It is reasonable to ask this question because ICD shocks may produce myocardial damage (37) and can be associated with increased mortality (38) . In COMPANION, the incidence of ICD shocks in the CRT-D arm was a nontrivial 24%, with 61% of them appropriate for sensed ventricular tachycardia or ventricular fibrillation (39). On post hoc analysis, the appropriate shocks were associated with an increased incidence of the primary endpoint ACM and PFD (39) . This is consistent with a separate analysis performed in a large cohort of more than 1,500 CRT-D-treated patients monitored daily from home, which reported that only appropriate shocks for sustained ventricular arrhythmias or atrial fibrillation or flutter predicted subsequent ACM compared with inappropriate shocks for noise, sinus tachycardia, or non-atrial fibrillation or flutter supraventricular tachycardia (38) . This suggests that it is the underlying rhythm rather than the shock per se that is associated with increased event rates, and perhaps many of these patients ultimately die of pump failure, resulting in no net mortality reduction from prevention of SCD.
Against an adverse effect of defibrillator shocks arm on pump failure outcomes in the CRT-D arm is that, unlike in the double and triple neurohormonal inhibition groups, an attenuation of the reduction in PFD in the CRT-D arm was not observed in the entire cohort (PFD hazard ratios vs. OPT: 0.70 for CRT-P and 0.72 for CRT-D) (Online Table 4 ). However, in support of an adverse effect of ICD shocks is the cardiac transplantation rate in the 2 CRT groups, which was 2.5-fold higher with CRT-D (n ¼ 15 [2.5%]) versus
Bristow et al. Heart Association class IV (6% [2] vs. 15% in COM-PANION) (Online Table 3 ), a higher LV ejection fraction (25% [2] vs. 21%) (Online Table 3 ), and a much lower percentage of patients with ischemic etiology (38% [2] vs. 56% in COMPANION) (Online Table 3 ).
Other baseline characteristics, including the intensity of pharmacological therapy, age, and IVCD characteristics were similar between the 2 trials (2) (Online Table 4 INSIGHTS GAINED. Heart failure trial implications. As indicated in Table 1 and Online Table 1 and the associated discussion, the COMPANION trial was successful despite formidable operational and design challenges.
In addition to the substantial effectiveness of the de- Along with beta-blockers (45), CRT is 1 of 2 medical therapies for HFrEF that produces "reverse remodeling," or decreases in LV volumes, an increase in ejection fraction, and regression of LV mass (13, 46, 47 
CONCLUSIONS
The results of the COMPANION trial were published, and the sponsor received FDA approval for not only the intermediate functional outcomes (23) but also the primary outcome, mortality plus hospitalization for any cause, and for mortality (52) . This "COM-PANION indication" is for patients with HFrEF who meet COMPANION inclusion criteria and remain symptomatic despite stable "optimal" heart failure therapy (53) . Currently optimal therapy may need to be revised to include ivabradine for persistently higher heart rates on a beta-blocker or sacubitrilvalsartan instead of an ACE inhibitor, but neither should compromise the effectiveness of CRT. 
